Welcome to our dedicated page for Adagene American Depositary Shares news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene American Depositary Shares stock.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company specializing in the discovery and development of novel antibody-based cancer immunotherapies. Co-founded by two serial entrepreneurs, Adagene aims to become a leader in antibody discovery and engineering. The company has developed a proprietary Dynamic Precision Library (DPL), showcasing its capabilities through a unique pipeline of innovative antibody therapeutics advancing into clinical trials.
The company's proprietary technologies, including NEObody™, SAFEbody®, and POWERbody™, enable the design of therapeutic antibody candidates with functional epitopes and cross-reactivity across species. These innovations are particularly focused on cancer immunotherapy, where Adagene’s pipeline features monoclonal antibody drugs targeting various cancers.
Adagene has raised over $86 million through three series of financing, with significant investments from F-Prime Capital, Eight Roads Ventures China, 6 Dimensions Capital, GP Healthcare Capital, Sequoia China, and New World TMT. The company utilizes computational biology and artificial intelligence to address unmet patient needs, striving to transform the discovery and development of therapies with enhanced safety and efficacy profiles.
One of Adagene’s key advancements is the development of ADG126, a masked anti-CTLA-4 SAFEbody, which is currently in clinical trials. Recent data highlighted no dose-limiting toxicities and compelling safety when combined with anti-PD-1 therapy. The results indicated tumor shrinkage in cold tumors and partial responses in multiple tumor types. Another notable candidate, ADG116, an unmasked anti-CTLA-4 NEObody, has also shown promising safety and anti-tumor activity in clinical trials.
Adagene’s strategic collaborations with global biopharmaceutical companies, including Roche, Sanofi, and Exelixis, emphasize the commercial potential of its antibody technologies. These partnerships leverage Adagene's platform for developing advanced therapies, including antibody-drug conjugates and bispecific antibodies, addressing a wide range of cancer types.
Financially, Adagene reported a cash balance of $143.8 million at the end of 2022, supporting streamlined operations into 2025. The company continues to prioritize its clinical programs and collaborations, aiming to maximize the therapeutic potential of its proprietary technologies.
For more information, please visit Adagene’s investor website.
Adagene Inc. (Nasdaq: ADAG) announced the dosing of the first patient in a phase 1b/2 trial for its anti-CD137 agonist ADG106 combined with anti-CTLA-4 mAb ADG116, targeting advanced solid tumors. This trial aims to evaluate safety and tolerability of the innovative combination, addressing unmet needs in cancer therapies. Both ADG106 and ADG116 have shown strong safety profiles and early efficacy signals in previous trials. The study is expected to set a new precedent for combination therapies in oncology, aligning with Adagene's mission to advance antibody-based cancer treatments.
Adagene Inc. (Nasdaq: ADAG) has appointed Dr. David Gandara to its Scientific and Strategic Advisory Board. Dr. Gandara is known for his expertise in cancer drug development and biomarker strategies. He expressed enthusiasm for Adagene's potential in advancing immuno-oncology treatments. Adagene CEO Peter Luo highlighted Gandara's insights as valuable, especially concerning the trial of ADG106 in combination with Nivolumab for non-small cell lung cancer. Dr. Gandara's extensive credentials enhance Adagene's leadership in the immunotherapy field.
Adagene Inc. (Nasdaq: ADAG) has initiated a phase 1b/2 clinical trial for ADG106, an anti-CD137 agonist antibody combined with nivolumab for advanced non-small cell lung cancer (NSCLC) patients. The trial, conducted in Singapore, aims to evaluate safety, tolerability, and efficacy in 53 patients who have progressed after prior treatments. Dr. Peter Luo mentioned the trial's potential to address resistance to anti-PD-1 therapy. This development is crucial, given that metastatic NSCLC is a leading cause of cancer-related deaths worldwide.
Adagene Inc. (Nasdaq: ADAG) announced a $3 million milestone payment triggered by the successful nomination of lead SAFEbody candidates in collaboration with Exelixis. This milestone underscores the efficacy of Adagene's SAFEbody precision masking technology in developing antibody-drug conjugates. The collaboration also included an upfront payment of $11 million and eligibility for further commercialization milestones and royalties. Adagene's pipeline includes several clinical-stage programs, with ongoing trials validating its SAFEbody technology in treating cancer.
Adagene (Nasdaq: ADAG) presented preclinical data at the 63rd American Society of Hematology Annual Meeting, highlighting two promising programs: ADG153, an anti-CD47 monoclonal antibody, and ADG152, a CD20xCD3 bispecific T-cell engager. ADG153 demonstrated reduced hematologic toxicities and an 8-fold prolonged half-life, while ADG152 showcased enhanced therapeutic index with minimized cytokine release. These findings support advancing both candidates into clinical development, showcasing Adagene's commitment to innovative cancer immunotherapies and the strength of its AI-driven antibody platform.
Adagene Inc. has presented promising clinical data on its anti-CTLA-4 monoclonal antibody ADG116 and anti-CD137 agonist ADG106 at the ESMO-IO Congress 2021. ADG116 showed a strong safety profile and early efficacy signals in patients with advanced solid tumors, with a notable 22% tumor reduction in a pancreatic cancer patient. Additionally, ADG106 demonstrated significant synergy with toripalimab, enhancing immune activation. These findings reinforce Adagene's commitment to developing innovative antibody-based immunotherapies and advancing its clinical pipeline.
Adagene presented promising clinical data for its monoclonal antibodies, ADG116 and ADG106, at the ESMO-IO Congress 2021. The ongoing trial of ADG116 indicated a strong safety profile with early efficacy signals in treatment-resistant tumors. Key findings included a 22% reduction in tumor size for a pancreatic cancer patient and evidence of immune activation. ADG106 showed enhanced immune response when combined with toripalimab. The trials aim to advance these therapies targeting advanced solid tumors, reinforcing Adagene's commitment to innovative cancer treatments.
Adagene has received FDA clearance for the IND application to initiate the Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody, ADG116, in combination with pembrolizumab. The global study (ADG116-P001) will target advanced metastatic solid tumors and will commence in early 2022 across multiple sites in the U.S. and Asia Pacific. This trial aims to evaluate safety, tolerability, and preliminary efficacy. Additionally, the ongoing ADG116-1003 trial will explore ADG116 in combinations with other therapies.
Adagene Inc. (Nasdaq: ADAG) announced two poster presentations at the ESMO-IO Congress 2021 showcasing clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116. The data highlight the potential of the NEObody™ technology in improving T-cell activation and safety profiles in cancer immunotherapy. Key presentations include biomarker kinetics for ADG106 and a dose-finding study for ADG116. The conference takes place from December 8-11, 2021, with details available after December 2.
Adagene Inc. (Nasdaq: ADAG) announced its participation in several investor and industry conferences throughout November 2021. Key events include one-on-one meetings during the Goldman Sachs Asia Pacific Healthcare Forum from November 15-17, its presentation at the 8th Annual BioCentury-BayHelix China Healthcare Summit from November 16-19, and on-demand viewing of its presentation at the Jefferies London Healthcare Conference starting November 18. Additionally, an on-demand presentation for the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available from November 22.
FAQ
What is the current stock price of Adagene American Depositary Shares (ADAG)?
What is the market cap of Adagene American Depositary Shares (ADAG)?
What is Adagene's main focus?
What technologies has Adagene developed?
Who are Adagene's significant investors?
What is the status of Adagene's clinical candidate ADG126?
What are some of Adagene's strategic collaborations?
What financial position did Adagene report at the end of 2022?
Where can I find more information about Adagene?
What is the significance of Adagene's technology collaborations?
Who co-founded Adagene?
What are the main therapeutic areas targeted by Adagene's pipeline?
